Toll‑like receptor 3 ligands for breast cancer therapies (Review)
Author:
Affiliation:
1. Department of Health Sciences, Faculty of Science, Wilfrid Laurier University, Waterloo, ON N2L 3C5, Canada
Publisher
Spandidos Publications
Subject
Cancer Research,Oncology
Reference61 articles.
1. Breast cancer epidemiology;Sancho-Garnier;Presse Med,2019
2. A guide to cancer immunotherapy: From T cell basic science to clinical practice;Waldman;Nat Rev Immunol,2020
3. Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead;Oiseth;J Cancer Metastitis Treat,2017
4. Trial watch: TLR3 agonists in cancer therapy;Le Naour;Oncoimmunology,2020
5. Toll-like receptor signaling pathways;Kawasaki;Frontiers Immunol,2014
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Participation of TLRs in cancer immunopathogenesis and drug resistance via interacting with immunological and/or non-immunological signaling pathways as well as lncRNAs;International Immunopharmacology;2024-10
2. Advances and prospects of RNA delivery nanoplatforms for cancer therapy;Acta Pharmaceutica Sinica B;2024-09
3. Toll-like receptors in breast cancer immunity and immunotherapy;Frontiers in Immunology;2024-06-06
4. Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial;Clinical and Translational Medicine;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3